Craft
  • Home
  •  / Sorrento Therapeutics
Sorrento Therapeutics

Sorrento Therapeutics

Revenue

$52.9 M

FY, 2021

Market Capitalization

$422.7 M

2022-11-22

Sorrento Therapeutics Summary

Company summary

Overview
Sorrento Therapeutics is a biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento's primary therapeutic focus is cancer although its products and technologies have much broader clinical applications including autoimmune disorders, metabolic diseases and infectious diseases. The Company's lead programs consist of four Phase III BioSimilar/BioBetter antibodies. It is also advancing a portfolio of adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates (ADCs).
Type
Public
Status
Active
Founded
2006
HQ
San Diego, CA, US | view all locations
Website
http://sorrentotherapeutics.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Henry Ji

    Henry Ji, Chairman, President, CEO

    • Mike Royal

      Mike Royal, Chief Medical Officer

      • Edgar Lee, Director

        • David Lemus, Director

          LocationsView all

          2 locations detected

          • San Diego, CA HQ

            United States

            4955 Directors Pl

          • San Diego, CA

            United States

            9380 Judicial Dr

          Sorrento Therapeutics Financials

          Summary financials

          Revenue (Q3, 2022)
          $17.4M
          Net income (Q3, 2022)
          ($90.6M)
          EBIT (Q3, 2022)
          ($109.4M)

          Footer menu